Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider

10 Oct 2025 12:36 CEST

Oslo, Norway, October 10, 2025 - Primary insider Michael Engsig, Chief Executive
Officer of Nykode Therapeutics ASA, has today acquired 55,944 shares in Nykode
Therapeutics ASA at a price of NOK 1.79 per share. Following the transaction,
Michael Engsig holds 71,794 shares in Nykode Therapeutics ASA.

Please see further details in the attached document.

More information:
Access the news on Oslo Bors NewsWeb site

656985_Attachment 251010.pdf